Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11512132 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

Patent 11512132 was granted and assigned to BeiGene, Ltd on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Yucheng Li0

Zhiying Ren0

Jing Song0

Tong Zhang0

Yanshen Kang0

Kang Li0

Date of Patent

November 29, 2022

0

Patent Application Number

167047380

Date Filed

December 5, 2019

0

Patent Citations

US Patent 10519235 Anti-PD1 antibodies and their use as therapeutics and diagnostics

US Patent 10005782 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators

US Patent 10058609 Antigen binding proteins that bind PD-L1

US Patent 10487147 Anti-PD-L1 antibodies and uses thereof

0

US Patent 10544225 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

US Patent 10550185 Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments

US Patent 10570139 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators

0

US Patent 10793632 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

0

...

Patent Citations Received

US Patent 12103931 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

US Patent 11591340 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

US Patent 11701357 Treatment of B cell cancers using a combination comprising Btk inhibitors

0

US Patent 11786529 Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

US Patent 11851437 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

US Patent 11884674 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

US Patent 11970500 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

US Patent 11999743 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11512132 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool